Zhizhuang Zhao to Myeloproliferative Disorders
This is a "connection" page, showing publications Zhizhuang Zhao has written about Myeloproliferative Disorders.
Connection Strength
1.810
-
Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice. J Hematol Oncol. 2014 Mar 19; 7:25.
Score: 0.455
-
Development of a highly sensitive method for detection of JAK2V617F. J Hematol Oncol. 2011 Oct 10; 4:40.
Score: 0.385
-
Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood. 2008 May 15; 111(10):5109-17.
Score: 0.300
-
HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression. Blood. 2022 05 05; 139(18):2797-2815.
Score: 0.200
-
Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera. PLoS One. 2020; 15(6):e0232801.
Score: 0.175
-
Relevance of JAK2V617F positivity to hematological diseases--survey of samples from a clinical genetics laboratory. J Hematol Oncol. 2011 Jan 14; 4:4.
Score: 0.091
-
Detection of the JAK2V617F mutation by asymmetric PCR and melt curve analysis. Cancer Biomark. 2007; 3(6):315-24.
Score: 0.069
-
JAK2(V617F): Prevalence in a large Chinese hospital population. Blood. 2007 Jan 01; 109(1):339-42.
Score: 0.067
-
miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2. JCI Insight. 2020 01 16; 5(1).
Score: 0.043
-
The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow. Neoplasia. 2011 Nov; 13(11):1058-68.
Score: 0.024